Biodexa Pharmaceticals (BDRX) - Net Assets
Based on the latest financial reports, Biodexa Pharmaceticals (BDRX) has net assets worth $11.38 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($18.15 Million) and total liabilities ($6.76 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check BDRX tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $11.38 Million |
| % of Total Assets | 62.74% |
| Annual Growth Rate | N/A |
| 5-Year Change | 8.92% |
| 10-Year Change | -75.1% |
| Growth Volatility | 1499.25 |
Biodexa Pharmaceticals - Net Assets Trend (2012–2025)
This chart illustrates how Biodexa Pharmaceticals's net assets have evolved over time, based on quarterly financial data. See Biodexa Pharmaceticals liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Biodexa Pharmaceticals (2012–2025)
The table below shows the annual net assets of Biodexa Pharmaceticals from 2012 to 2025. For live valuation and market cap data, see BDRX company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $11.38 Million | +36.81% |
| 2024-12-31 | $8.32 Million | +77.90% |
| 2023-12-31 | $4.68 Million | +47.94% |
| 2022-12-31 | $3.16 Million | -69.75% |
| 2021-12-31 | $10.45 Million | +55.59% |
| 2020-12-31 | $6.72 Million | -65.65% |
| 2019-12-31 | $19.56 Million | +15.56% |
| 2018-12-31 | $16.92 Million | -51.19% |
| 2017-12-31 | $34.68 Million | -24.16% |
| 2016-12-31 | $45.72 Million | -2.48% |
| 2015-12-31 | $46.89 Million | +11.66% |
| 2014-12-31 | $41.99 Million | +5424.87% |
| 2013-12-31 | $760.00K | +109.18% |
| 2012-12-31 | $-8.28 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Biodexa Pharmaceticals's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 7467545300.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $14.07 Million | 123.62% |
| Other Comprehensive Income | $1.19 Million | 10.42% |
| Other Components | $98.75 Million | 867.37% |
| Total Equity | $11.38 Million | 100.00% |
Biodexa Pharmaceticals Competitors by Market Cap
The table below lists competitors of Biodexa Pharmaceticals ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Totalindo Eka Persada Tbk PT
JK:TOPS
|
$1.95 Million |
|
KEY Petroleum Ltd
AU:KEY
|
$1.96 Million |
|
Verney-Carron S.A
PA:MLVER
|
$1.96 Million |
|
Savannah Resources Plc
LSE:SAV
|
$1.96 Million |
|
Kovo Healthtech Corp
V:KOVO
|
$1.95 Million |
|
Winsome Yarns Limited
NSE:WINSOME
|
$1.95 Million |
|
Urban-Gro Inc
NASDAQ:UGRO
|
$1.95 Million |
|
DigiAsia Corp
NASDAQ:FAAS
|
$1.94 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Biodexa Pharmaceticals's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 8,322,000 to 11,384,953, a change of 3,062,953 (36.8%).
- Net loss of 6,244,097 reduced equity.
- New share issuances of 13,749,000 increased equity.
- Other comprehensive income decreased equity by 51,817,089.
- Other factors increased equity by 47,375,139.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-6.24 Million | -54.85% |
| Share Issuances | $13.75 Million | +120.76% |
| Other Comprehensive Income | $-51.82 Million | -455.14% |
| Other Changes | $47.38 Million | +416.12% |
| Total Change | $- | 36.81% |
Book Value vs Market Value Analysis
This analysis compares Biodexa Pharmaceticals's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.01x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $6519333.33 | $3.01 | x |
| 2020-12-31 | $6718000.00 | $3.01 | x |
| 2021-12-31 | $10452469.00 | $3.01 | x |
| 2022-12-31 | $3162000.00 | $3.01 | x |
| 2023-12-31 | $155933.33 | $3.01 | x |
| 2024-12-31 | $134.33 | $3.01 | x |
| 2025-12-31 | $207.52 | $3.01 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Biodexa Pharmaceticals utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -54.85%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.59x
- Recent ROE (-54.85%) is above the historical average (-117.12%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.17 Million |
| 2013 | -537.37% | -2778.23% | 0.03x | 6.81x | $-4.16 Million |
| 2014 | -21.01% | -5619.11% | 0.00x | 1.11x | $-13.02 Million |
| 2015 | -21.54% | -734.47% | 0.02x | 1.37x | $-14.79 Million |
| 2016 | -13.47% | -465.68% | 0.02x | 1.24x | $-10.73 Million |
| 2017 | -33.76% | -1183.52% | 0.02x | 1.42x | $-15.17 Million |
| 2018 | -61.26% | -534.98% | 0.09x | 1.21x | $-12.06 Million |
| 2019 | -51.56% | -1496.29% | 0.02x | 1.58x | $-12.04 Million |
| 2020 | -330.29% | -6469.10% | 0.03x | 1.46x | $-22.86 Million |
| 2021 | -52.24% | -944.64% | 0.04x | 1.24x | $-6.51 Million |
| 2022 | -242.13% | -1095.28% | 0.13x | 1.75x | $-7.97 Million |
| 2023 | -151.33% | -1858.01% | 0.04x | 2.25x | $-7.55 Million |
| 2024 | -68.84% | 0.00% | 0.00x | 1.78x | $-6.56 Million |
| 2025 | -54.85% | 0.00% | 0.00x | 1.59x | $-7.38 Million |
Industry Comparison
This section compares Biodexa Pharmaceticals's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $155,285,360
- Average return on equity (ROE) among peers: -101.11%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Biodexa Pharmaceticals (BDRX) | $11.38 Million | 0.00% | 0.59x | $1.95 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $83.17 Million |
| Abcellera Biologics Inc (ABCL) | $830.51 Million | 14.32% | 0.21x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $-26.99 Million | 0.00% | 0.00x | $321.39 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $182.50 Million | -46.25% | 0.30x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $4.59 Million | -357.76% | 1.38x | $35.10 Million |
| Abivax SA American Depositary Shares (ABVX) | $33.94 Million | -14.97% | 0.12x | $7.98 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $113.93 Million | -49.49% | 0.18x | $3.66 Billion |
About Biodexa Pharmaceticals
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan brain cancer. Its lead product candidate, Tolimidone, is a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment … Read more